Completed PHASE4 INTERVENTIONAL 2-arm NCT02025608

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome (AUTOREST)

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS

Sponsor: Cardiocentro Ticino

Conditions Restless Legs Syndrome

Interventions Placebo Pramipexole

Updated 7 times since 2017 Last updated: Jan 23, 2017 Started: Dec 31, 2013 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02025608, this PHASE4 trial focuses on Restless Legs Syndrome and remains completed. Sponsored by Cardiocentro Ticino, it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jul 2023 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2023 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cardiocentro Ticino
Insel Gruppe AG, University Hospital Bern
Mauro Manconi

Data source: Ospedale Regionale di Lugano

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bern, Switzerland
• Lugano, Switzerland